2 completed. 2 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
| Phase 3 | 1 | Completed 1 |
Follow Micropapillary Serous Carcinoma: new trials by email Literature Review of Micropapillary Serous Carcinoma trials Research Report on Micropapillary Serous Carcinoma
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Trametinib in Treating Patients With Recurrent or Progressive Low-Grade Ovarian Cancer or Peritoneal Cavity Cancer Letrozole, Paclitaxel, Pegylated Liposomal Doxorubicin Hydrochloride - Borderline Ovarian Serous Tumor, Micropapillary Serous Carcinoma | Phase 2 / Phase 3 | Completed | National Cancer Institute (NCI) | 260 | 2014-04-11 | 2026-08-04 |
| Selumetinib Sulfate in Treating Woman With Recurrent Low-Grade Ovarian Cancer or Peritoneum Cancer Laboratory Biomarker Analysis, Pharmacological Study, Selumetinib - Borderline Ovarian Serous Tumor, Low Grade Ovarian Serous Adenocarcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 52 | 2007-12-17 | 2020-12-03 |
Cystadenocarcinoma, Serous (2)
Adenocarcinoma (2) · Carcinoma (2) · Cystadenocarcinoma (2) · Neoplasms (2) · Neoplasms by Histologic Type (2) · Neoplasms, Cystic, Mucinous, and Serous (2) · Neoplasms, Glandular and Epithelial (2)
AZD 6244 (1) · Doxorubicin (1) · Letrozole (1) · Paclitaxel (1) · Tamoxifen (1) · Taxes (1) · Topotecan (1) · liposomal doxorubicin (1) · trametinib (1)
National Cancer Institute (NCI) (2)
United States (2) · United Kingdom (1)
David M Gershenson (1) · John H Farley (1)
U10CA180868 (2), P50CA083639 (1), U10CA027469 (1)